Eliem Therapeutics analyst ratings
Eliem Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/11/2022 | 142.59% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 250.4% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 762.53% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 843.4% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 789.49% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 11 月 7 日 | 142.59% | SVB Leerink | 13 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 04/26/2022 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 04/26/2022 | 250.4% | SVB Leerink | 33 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 09/07/2021 | 762.53% | 古根海姆 | → 32 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/07/2021 | 843.4% | Stifel | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/07/2021 | 789.49% | SVB Leerink | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Eliem Therapeutics Questions & Answers
Eliem Therapeutics 問題與解答
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by SVB Leerink on July 11, 2022. The analyst firm set a price target for $9.00 expecting ELYM to rise to within 12 months (a possible 142.59% upside). 6 analyst firms have reported ratings in the last year.
SVB Leerink於2022年7月11日公佈了Eliem Therapeutics（納斯達克股票代碼：ELYM）的最新目標股價。該分析公司將目標股價定爲9.00美元，預計ELYM將在12個月內升至12個月內（可能上漲142.59％）。去年有6家分析公司公佈了評級。
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by SVB Leerink, and Eliem Therapeutics maintained their outperform rating.
Eliem Therapeutics（納斯達克股票代碼：ELYM）的最新分析師評級由SVB Leerink提供，Eliem Therapeutics維持跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on July 11, 2022 so you should expect the next rating to be made available sometime around July 11, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Eliem Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Eliem Therapeutics的最新評級是在2022年7月11日發佈的，因此您應該預計下一個評級將在2023年7月11日左右公佈。
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a maintained with a price target of $13.00 to $9.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.71, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Eliem Therapeutics（ELYM）評級保持不變，目標股價爲13.00美元至9.00美元。Eliem Therapeutics（ELYM）目前的交易價格爲3.71美元，超出了分析師的預期區間。